Prob |
Study design/subjects |
Sample size |
Study period |
Advantage |
Disadvantage |
Ref |
Lactobacillus acidophilus NCFM® (1010 CFU) |
Double-blinded, randomized, placebo-controlled, T2D males. Ages: 48-65 years-old |
Prob: n = 21 Cont: n = 24 |
4 weeks |
↑ insulin sensitivity |
No alteration in the inflammatory markers (TNF, IL-6, IL-1ra and CRP) |
91
91. Andreasen A, Larsen N, Pedersen-Skovsgaard T, Berg R, Møller K, Svendsen KD, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. British J Nutr. 2010; 104: 1831-8.
|
Lactobacillus acidophilus (2 ×109CFU); L. casei (7×109 CFU); L. rhamnosus (1.5×109 CFU); L. bulgaricus (2×108 CFU); Bifidobacterium breve (2×1010 CFU); B. longum (7×109 CFU), Streptococcus thermophilus (1.5×109CFU) |
Randomized, double-blinded, placebo-controlled, T2D males and females. Ages: 35-70 years-old |
Prob: n = 27 Cont: n = 27 |
8 weeks |
↓ FPG and CRP |
No alteration in the serum insulin levels and HOMA-IR |
92
92. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013; 63(1-2): 1-9.
|
Lactobacillus sporogenes (1×107 CFU) + 0.04 g inulin (as prebiotic) |
Randomized, placebo-controlled, T2D. Ages: 35-70 years-old |
Prob: n = 35 Cont: n = 35 |
6 weeks |
↓ Insulin and CRP |
No alteration in the HOMA-IR and FPG |
93
93. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr. 2014; 33(2): 198-203.
|
Lactobacillus acidophilus (4x108 CFU/100mL); Bifidobacterium bifidum (4x108 CFU/100mL) |
Randomized, double-blind, placebo-controlled, T2D females. Ages: 50-60 years-old |
Prob: n = 10 Cont: n = 10 |
5.5 weeks |
↓ FPG and Glycemia |
--- |
94
94. Moroti C, Magri LFS, Costa MR, Cavallini DCU, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012; 11: 29.
|
Lactobacillus acidophilus La-5 (109 CFU); Bifidobacterium animalis subsp lactis BB-12 (109 CFU) |
Randomized, double-blind, placebo-controlled, T2D patients. Ages: 35-60 years-old |
Prob: n = 23 Cont: n = 22 |
6 weeks |
↓ HbA1c and TNF- α (both groups) |
No alteration in the IL-10 and IL-6 levels |
95
95. Tonucci LB, Dos Santos KMO, Oliveira LL, Ribeiro SMR, Martino HSD. Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr. 2017; 36(1): 85-92.
|
Lactobacillus casei (4×1010 CFU) |
Randomized, placebo-controlled, T2D patients. Ages: 30-79 years-old |
Prob: n = 34 Cont: n = 34 |
16 weeks |
↑ Counts of the total Lactobacillus and L. casei subgroup ↑ Counts of the total Clostridium coccoides group and the C. leptum subgroup ↓ L. gasseri and L. reuteri subgroups ↓ Translocation of gut bacteria to the blood |
No alteration in the HbA1c, FPG, and inflammatory markers (LBP, IL-6, TNF-α, CRP) |
96
96. Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017; 7(1): 1-10.
|
Lactobacillus acidophilus La5 (7.23x106 CFU/g); Bifidobacterium lactis Bb12 (6.04x106 CFU/g) |
Randomized, double-blind, controlled clinical, T2DM. Ages: 30-60 years-old |
Prob: n = 30 Cont: n = 30 |
6 weeks |
↓ FPG and HbA1c |
No alteration in the insulin levels |
97
97. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012; 28(5): 539-43.
|
Lacticaseibacillus paracasei (3x108 CFU) strain Shirota (previously Lactobacillus casei strain Shirota); Bifidobacterium breve (3x108 CFU) strain Yakult, and galactooligosaccharides) |
Randomized, double-blind, controlled clinical, T2DM and obese patients. Ages: 30-80 years-old |
Prob: n = 44 Cont: n = 42 |
24 weeks |
↑ B. adolescentis, B. pseudocatenulatum, Lactobacillus ↓ B. vulgatus
|
↑ levels of FPG and HbA1c (12 weeks) No alteration in the glycemia and inflammatory markers (IL-6, LBP, CRP) |
98
98. Kanazawa A, Aida M, Yoshida Y, Kaga H, Katahira T, Suzuki L, et al. Effects of synbiotic probiotication on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: a randomized controlled study. Nutrients. 2021; 13: 558.
|
Lactobacillus acidophilus (2×109 CFU); Lactobacillus casei (7×109 CFU); Lactobacillus rhamnosus (1.5×109 CFU); Lactobacillus bulgaricus (2×108 CFU); Bifidobacterium breve (3×1010 CFU); Bifidobacterium longum (7×109 CFU); Streptococcus thermophilus (1.5×109 CFU) |
Randomized, double-blind, controlled clinical, T2DM. Ages: 30-75 years-old |
Prob: n = 30 Cont: n = 30 |
6 weeks |
↓ FPG |
No alteration in the insulin levels |
99
99. Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial. Diabetes Metab Syndr. 2019; 13(1): 175-82.
|
Lactobacillus casei (108 CFU/L) |
Block randomized, controlled clinical, T2DM. Ages: 30-50 years-old |
Prob: n = 20 Cont: n = 20 |
8 weeks |
↓ FPG, serum insulin level, and HOMA-IR |
No alteration in the HbA1c |
100
100. Khalili L, Alipour B, Jafar-Abadi MA, Faraji I, Hassanalilou T, Abbasi MM. The effects of Lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus: a randomized controlled trial. Iran Biomed J. 2019; 23(1): 68.
|
Lactobacillus + Lactococcus (6×1010 CFU/g); Bifidobacterium (1×1010 CFU /g); Propionibacterium (3×1010 CFU/g); Acetobacter (1×106 CFU /g) |
Randomized, double-blind, controlled clinical, T2D. Ages: 18-75 years-old |
Prob: n = 31 Cont: n = 22 |
8 weeks |
↓ HbA1c and HOMA-IR |
↑ TNF-α, IL-1β, IL-6, INF- γ levels No alteration in the FPG and serum insulin and IL-8 levels |
101
101. Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D, Komissarenko I. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial. Diabetes Metab Syndr. 2018; 12(5): 617-24.
|
Lactobacillus salivarius (subsp. salicinius AP-32); Lactobacillus johnsonii (MH-68); Bifidobacterium animalis (subsp. lactis CP-9) contain 1×1010 CFU/day) |
Randomized, double-blind, placebo-controlled trial. T1DM. Ages: 6-18 years-old |
Prob: n = 27 Cont: n = 29 |
24 weeks |
↑ B. animalis, Akkermansia muciniphila and Lactobacillus salivarius in the gut ↓ FPG, HbA1c, IL-8, IL-17, MIP-1β, TNF-α ↑ TGF-β |
--- |
102
102. Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, et al. Adjuvant probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 attenuate glycemic levels and inflammatory cytokines in patients with type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2022; 13: 754401.
|